Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
RNA interference therapeutics targeting angiotensinogen ameliorate preeclamptic phenotype in rodent models
Nadine Haase, … , Babbette LaMarca, Ralf Dechend
Nadine Haase, … , Babbette LaMarca, Ralf Dechend
Published April 27, 2020
Citation Information: J Clin Invest. 2020;130(6):2928-2942. https://doi.org/10.1172/JCI99417.
View: Text | PDF
Research Article Reproductive biology Article has an altmetric score of 45

RNA interference therapeutics targeting angiotensinogen ameliorate preeclamptic phenotype in rodent models

  • Text
  • PDF
Abstract

Authors

Nadine Haase, Donald J. Foster, Mark W. Cunningham, Julia Bercher, Tuyen Nguyen, Svetlana Shulga-Morskaya, Stuart Milstein, Sarfraz Shaikh, Jeff Rollins, Michaela Golic, Florian Herse, Kristin Kräker, Ivo Bendix, Meray Serdar, Hanna Napieczynska, Arnd Heuser, Alexandra Gellhaus, Kristin Thiele, Gerd Wallukat, Dominik N. Müller, Babbette LaMarca, Ralf Dechend

×

Figure 3

siRNA against hAgt reduces mean arterial pressure and albuminuria.

Options: View larger image (or click on image) Download as PowerPoint
siRNA against hAgt reduces mean arterial pressure and albuminuria.
(A) E...
(A) Effect of luciferase-targeting siRNA or hAgt-targeting siRNA on mean arterial pressure (MAP) in preeclamptic (PE) rats. MAP measured by telemetry was reduced in hAgt-targeting siRNA–treated (n = 9) compared with luciferase-targeting siRNA–treated (n = 5) PE rats (*P < 0.01, #P < 0.5; 2-way ANOVA with Bonferroni’s post hoc test; mean ± SEM). (B) Effect of luciferase-targeting siRNA or hAgt-targeting siRNA on albuminuria in PE rats. Albuminuria was normalized by hAgt-targeting siRNA treatment (n = 9) compared with luciferase-targeting siRNA treatment (n = 10) (***P < 0.001; unpaired t test; mean ± SEM). (C) Effect of luciferase-targeting siRNA or hAgt-targeting siRNA on Ngal mRNA expression levels in maternal liver and kidney tissue of PE rats. Ngal expression was significantly reduced in maternal kidney of hAgt-targeting versus luciferase-targeting siRNA–treated rats (n = 5 each; *P < 0.05; Mann-Whitney test; mean ± SEM).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 6 news outlets
Posted by 5 X users
51 readers on Mendeley
See more details